Demographic and psychosocial evaluation | Clinical assessment | Laboratory evaluation | |
---|---|---|---|
Active TB Cohort (n=1200) | Socioeconomic status Health-seeking behaviour Alcohol consumption Smoking history Secondhand smoke exposure HRQOL Household food insecurity Medication adherence Objective AP assessments | Medical history* Medication history† Targeted physical examination Anthropometry Lung Health assessments | AFB microscopy Mycobacterial culture and DST Xpert MTB/Rif Histopathology for EPTB HIV test and CD4 enumeration Liver function tests HbA1c, CBC Urine pregnancy test Chest X-ray Population PK for 1st-line drugs Sputum microbiome analysis |
HH Contact Cohort (n=3200) | Health-seeking behaviour Alcohol consumption Smoking history Secondhand smoke exposure HRQOL Medication adherence Objective AP assessments | Medical history* Medication history† Targeted physical examination Anthropometry Exposure gradient Lung Health assessments | AFB microscopy Mycobacterial culture and DST TST and QGIT HIV test and CD4 enumeration HbA1c CBC Urine pregnancy test Chest X-ray |
Control Cohort (n=500) | Socioeconomic status Health-seeking behaviour Alcohol consumption Smoking history Secondhand smoke exposure HRQOL Household food insecurity Medication adherence | Medical history* Medication history Targeted physical examination Anthropometry | TST and QGIT HIV test and CD4 enumeration HbA1c, CBC Urine pregnancy test Chest X-ray |
*Includes history of BCG vaccination and previous TST or Interferon γ release assay testing.†Includes history of current or previous isoniazid prophylaxis.
AFB, acid-fast bacilli; AP, air pollution exposure; ATT, antituberculosis treatment; CBC, complete blood count; DST, drug sensitivity testing; EPTB, extrapulmonary TB; HbA1c, glycated haemoglobin for DM; HH, household; HRQOL, Health-Related Quality of Life; n, Target sample size; PK, pharmacokinetics; QGIT, Quantiferon Gold in Tube; TST, tuberculin skin test.